Bone and soft tissue sarcoma
Conditions
Interventions
Helical Tomotherapy (TOMO) Low-dose Whole Abdominopelvic Irradiation Combined with Simultaneous Integrated Boost Group:1. Whole abdominopelvic baseline dose: 15 Gy/10 fractions (1.5 Gy/fraction) for p
sequential boost to =45 Gy/25 fractions if SIB is not feasible
Sponsors
Peking University Shougang Hospital
Eligibility
Sex/Gender
All
Age
6 Years to 39 Years
Inclusion criteria
Inclusion criteria: 1. Histologically confirmed highly radiosensitive bone/soft tissue sarcoma, including desmoplastic small round cell tumor (DSRCT), Ewing sarcoma, rhabdomyosarcoma, myxoid liposarcoma, etc. 2. Imaging-confirmed abdominopelvic involvement (metastasis, peritoneal seeding, malignant ascites, tumor rupture, or intraoperative contamination requiring whole abdominopelvic radiotherapy). 3. Age 6–39 years (including pediatric, adolescent, and young adult populations). 4. Karnofsky Performance Status (KPS) >=60%. 5. Expected survival >=3 months. 6. Adequate cardiopulmonary, hepatic, and renal function to tolerate radiotherapy (e.g., FEV1 >=50% predicted, NYHA class I–II, normal or mildly abnormal organ function). 7. Informed consent signed by the patient or legal representative.
Exclusion criteria
Exclusion criteria: 1. Previous abdominal/pelvic radiotherapy with unacceptable risk of normal tissue injury. 2. Active infection, uncontrolled diabetes, severe hypertension, unstable angina, heart failure, or other severe comorbidities. 3. Uncontrolled massive malignant ascites, complete intestinal obstruction, or active gastrointestinal bleeding. 4. Severe hepatic/renal insufficiency (decompensated cirrhosis, chronic renal failure). 5. Pregnant or lactating women. 6. Mental or cognitive impairment, or inability to comply with treatment. 7. Concurrent participation in another interventional clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of grade >=3 acute non-hematological toxicities during treatment and within 3 months post-treatment;Incidence of all-grade acute and late toxicities; | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment planning success rate;Objective response rate (ORR);Disease control rate (DCR);Abdominopelvic progression-free survival (abPFS);Overall survival (OS);Patient quality of life (QoL);Target and organ-at-risk (OAR) dosimetric parameters; | — |
Countries
China
Contacts
Public ContactYuanyou Yang
Peking University Shougang Hospital
Outcome results
None listed